Actuate Therapeutics proposes 50 million share offering
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Actuate Therapeutics, Inc. is proposing a primary offering of 50,000,000 shares of common stock at an assumed price of $0.819 per share, with an underwriter option for an additional 7,500,000 shares. The clinical-stage biopharmaceutical company plans to use net proceeds for working capital and general corporate purposes. The offering comes as Actuate needs to regain compliance with Nasdaq's $50 million minimum market value of listed securities requirement by January 11, 2027.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.